



For immediate release 07:00: 13 April 2015

RETROSCREEN VIROLOGY GROUP PLC
("Retroscreen" or the "Company")

CHANGE OF NAME TO HVIVO PLC

As detailed in its H1'14 Half Year Financial Report announced on 25 September 2014, Retroscreen will be changing its name to hVIVO plc which is currently the Company's proprietary name for its technology platform. The Company's change of name is being registered at Companies House and is expected to become effective on 16 April 2015.

Trading in the Company's shares on AIM under the new name of hVIVO plc (AIM: HVO) is expected to take effect from 8.00am on 16 April 2015.

A further announcement will be made as soon as the name change has taken effect.

For further information please contact:

Retroscreen Virology Group plc

+44 207 756 1300

Kym Denny (CEO)
Graham Yeatman (FD)

Media Enquiries

+44 203 021 3933 / +44 7854 979 420

Colin Paterson (Director of Marketing, Communication and Public Relations)

Numis Securities Limited

+44 207 260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)

Notes to Editors:

Retroscreen Virology Group plc ("Retroscreen") is a rapidly growing life sciences company pioneering human models of disease to accelerate drug development and promote disease understanding. Based in the UK, Retroscreen has conducted over 40 clinical studies, involving more than 1900 volunteers for a range of leading industry, governmental and academic clients.